Table 4: Funding approved for UQD initiatives, January 2017 ($ million)

	Grant Name	Principal Recipient	Approved Funding	Revised UQD2
Bangladesh (TB)	BGD-T-BRAC	BRAC	1.9 m	19.2 m
	BGD-T-NTP	National TB Program	2.1 m
C.A.R. (TB/HIV)	CAF-C-IFRC	IFRC	4.6 m1	NIL
Philippines (TB)	PHL-T-PBSP	Philippine Business for Social Progress	5.3 m	NIL
Viet Nam (TB)	VNM-T-NTP	National TB Program	3.0 m	36.8 m
Myanmar (TB)	MYN-T-SCF	Save the Children	5.1 m	12.0 m3
	MYN-T-UNOPS	UNOPS
TOTALS			22.0 m	68.0 m

Below, we provide additional information on the UQD initiatives listed in Table 4. Unless otherwise indicated, the source of the funding is portfolio optimization. The Philippines was awarded $5.3 million to implement initiatives that were on the UQD register. The additional investment will focus on scaling up coverage of programmatic management of drug-resistant TB. The program aims to enrol an additional 1,100 MDR-TB patients in 2017 by transitioning newly enrolled patients to shorter regimen treatment. Activities supported by additional funds include procuring pharmaceuticals, health products and equipment; providing living support to patients; and expanding the decentralization of programmatic management of drug-resistant TB. The $3 million in additional funding for Viet Nam will be used to conduct TB active case finding in communities in 24 additional districts in eight provinces; to expand the use of the nine-month regimen for MDR-TB treatment; to increase the percentage of notified cases of bacteriologically confirmed, drug resistant, Rifampacin-resistant TB or MDR-TB from 20.5% in 2013 to 65.6% in 2017; and to increase the percentage of HIV-positive registered ART patients undergoing TB treatment from 60.5% in 2013 to 90% in 2017. The Central African Republic was awarded $4.6 million. The interventions that will be implemented with this money include the following: expanding ART; strengthening the capacity of the TB and HIV national programs; decentralizing MDR-TB case management through the procurement of GeneXpert machines and training of health and lab workers in three additional sites; and scaling up viral load testing. Bangladesh received $4 million for UQD initiatives. Half of that money came from portfolio optimization. The other half came from a contribution made by Comic Relief, a private sector donor. The additional investment will be used to expand the public-private mix in Bangladesh, focusing on a social enterprise model which has already been run as a successful pilot in three TB screening centers in Dhaka since 2014; and using a similar model to reach new urban settings and to leverage BRAC’s extensive networks into the community. The $5.1 million for Myanmar to fund UQD initiatives has been integrated into the budget for Myanmar TB/HIV early applicant funding (see Table 3).